Platform
Team
Careers
Press
Contact
Press
The latest from Terray.
Odyssey Therapeutics and Terray Therapeutics Enter Strategic Collaboration to Jointly Discover and Develop First-in-Class Transcription Factor Therapies
Press Release
•
October 28, 2024
Terray Therapeutics Closes Oversubscribed $120M Series B to Advance Its Generative AI Pipeline of Small Molecule Therapeutics to the Clinic
Press Release
•
October 17, 2024
How A.I. Is Revolutionizing Drug Development
The New York Times
•
June 17, 2024
Terray Therapeutics Announces Multi-Target Collaboration with Bristol Myers Squibb
Press Release
•
December 14, 2023
Terray Therapeutics Announces Investment from NVIDIA to Enable Generative AI Design for Drug Discovery
Press Release
•
November 9, 2023
Terray Therapeutics Strengthens Leadership with Appointment of Sudha Parasuraman, MD to its Board of Directors
Press Release
•
May 16, 2023
Terray Therapeutics Appoints John Maraganore, Ph.D., as Strategic Advisor
Press Release
•
December 13, 2022
Terray Therapeutics Strengthens Leadership with Appointment of Bassil Dahiyat, Ph.D., as Board Independent Director
Press Release
•
November 30, 2022
Terray Therapeutics and Calico Enter into a Multi-Target Collaboration to Discover Small Molecule Therapeutics for Age-Related Diseases
Press Release
•
October 12, 2022
Terray Therapeutics Expands Scientific Advisory Board to Advance AI-Driven Small Molecule Drug Discovery
Press Release
•
July 12, 2022
Terray Therapeutics Expands Leadership Team with Fez Ujjainwalla, PhD as Head of Business
Press Release
•
March 1, 2022
Founded and Funded – Terray Therapeutics Building an Intersection of Innovation Company
Madrona Venture Group
•
February 27, 2022
Terray Therapeutics Launches with $60M to Deliver Premium Chemical Data at Unrivaled Scale, Unlocking the Potential of AI-Driven Small Molecule Drug Discovery
Press Release
•
February 15, 2022
LinkedIn
Privacy
Terms
© 2024 Terray Therapeutics, Inc.